(RGNX) Regenxbio - Ratings and Ratios
Gene Therapy, Biotechnology, NAV Technology, Viral Vectors, Genetic Treatments
RGNX EPS (Earnings per Share)
RGNX Revenue
Description: RGNX Regenxbio
REGENXBIO Inc. is a clinical-stage biotechnology company focused on developing gene therapies for various genetic diseases. Their proprietary NAV Technology Platform is the foundation for their product pipeline, which includes treatments for wet age-related macular degeneration, Duchenne muscular dystrophy, and other rare genetic disorders. The companys lead product candidates, such as ABBV-RGX-314 and RGX-202, are in advanced stages of clinical trials, indicating a potential for near-term milestones.
From a business perspective, REGENXBIO has established strategic partnerships, including a collaboration with AbbVie to develop ABBV-RGX-314 outside the United States. This partnership not only validates the companys technology but also provides a potential source of revenue through milestone payments and royalties. Additionally, the companys NAV Technology Platform is licensed to other biotechnology and pharmaceutical companies, generating revenue through licensing fees.
Key performance indicators (KPIs) to monitor for REGENXBIO include the progression of their clinical trials, particularly the Phase III trial for RGX-202 in Duchenne muscular dystrophy. Other important metrics include the revenue generated from their licensing agreements, the cash runway, and the companys ability to secure new partnerships or collaborations. As a clinical-stage company, RGNXs stock price is likely to be sensitive to news flow from their clinical trials, making it essential to track updates on patient enrollment, trial timelines, and interim results.
From a financial perspective, REGENXBIOs market capitalization is approximately $461.56 million, with a negative return on equity (ROE) of -53.29%, indicating significant investment in research and development. The absence of a price-to-earnings (P/E) ratio is not surprising, given the companys focus on R&D and lack of profitability. As the company progresses through clinical trials and potentially brings products to market, investors will be watching for signs of revenue growth and eventual profitability.
RGNX Stock Overview
| Market Cap in USD | 498m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2015-09-17 |
RGNX Stock Ratings
| Growth Rating | -66.5% |
| Fundamental | 30.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -38.8% |
| Analyst Rating | 4.42 of 5 |
RGNX Dividends
Currently no dividends paidRGNX Growth Ratios
| Growth Correlation 3m | 49% |
| Growth Correlation 12m | -21.6% |
| Growth Correlation 5y | -94.6% |
| CAGR 5y | -28.74% |
| CAGR/Max DD 3y | -0.36 |
| CAGR/Mean DD 3y | -0.72 |
| Sharpe Ratio 12m | -1.41 |
| Alpha | 0.05 |
| Beta | 0.905 |
| Volatility | 61.60% |
| Current Volume | 290.8k |
| Average Volume 20d | 449.8k |
| Stop Loss | 8.6 (-7.1%) |
| Signal | 0.62 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-175.6m TTM) > 0 and > 6% of Revenue (6% = 9.35m TTM) |
| FCFTA -0.30 (>2.0%) and ΔFCFTA 9.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 163.2% (prev 279.0%; Δ -115.8pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -87.9m > Net Income -175.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (51.5m) change vs 12m ago 1.74% (target <= -2.0% for YES) |
| Gross Margin 79.94% (prev 42.66%; Δ 37.27pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 27.08% (prev 15.64%; Δ 11.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.89 (EBITDA TTM -129.9m / Interest Expense TTM 29.8m) >= 6 (WARN >= 3) |
Altman Z'' -7.28
| (A) 0.44 = (Total Current Assets 373.8m - Total Current Liabilities 119.5m) / Total Assets 581.0m |
| (B) -1.72 = Retained Earnings (Balance) -996.9m / Total Assets 581.0m |
| warn (B) unusual magnitude: -1.72 — check mapping/units |
| (C) -0.25 = EBIT TTM -145.8m / Avg Total Assets 575.2m |
| (D) -2.72 = Book Value of Equity -997.7m / Total Liabilities 367.3m |
| Total Rating: -7.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.20
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -37.28% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 1.39 = 1.61 |
| 5. Debt/Ebitda -2.28 = -2.50 |
| 6. ROIC - WACC (= -62.54)% = -12.50 |
| 7. RoE -66.95% = -2.50 |
| 8. Rev. Trend 21.78% = 1.63 |
| 9. EPS Trend 59.18% = 2.96 |
What is the price of RGNX shares?
Over the past week, the price has changed by -6.37%, over one month by +6.31%, over three months by +1.09% and over the past year by -27.32%.
Is Regenxbio a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RGNX is around 6.32 USD . This means that RGNX is currently overvalued and has a potential downside of -31.75%.
Is RGNX a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RGNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.8 | 221.3% |
| Analysts Target Price | 29.8 | 221.3% |
| ValueRay Target Price | 7 | -24.9% |
Last update: 2025-09-05 04:57
RGNX Fundamental Data Overview
CCE Cash And Equivalents = 323.3m USD (Cash And Short Term Investments, last quarter)
P/S = 3.1972
P/B = 2.3333
P/EG = 0.26
Beta = 1.108
Revenue TTM = 155.8m USD
EBIT TTM = -145.8m USD
EBITDA TTM = -129.9m USD
Long Term Debt = 247.8m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 48.4m USD (from shortTermDebt, last quarter)
Debt = 296.2m USD (Calculated: Short Term 48.4m + Long Term 247.8m)
Net Debt = 192.1m USD (from netDebt column, last quarter)
Enterprise Value = 470.9m USD (498.1m + Debt 296.2m - CCE 323.3m)
Interest Coverage Ratio = -4.89 (Ebit TTM -145.8m / Interest Expense TTM 29.8m)
FCF Yield = -37.28% (FCF TTM -175.6m / Enterprise Value 470.9m)
FCF Margin = -112.7% (FCF TTM -175.6m / Revenue TTM 155.8m)
Net Margin = -112.7% (Net Income TTM -175.6m / Revenue TTM 155.8m)
Gross Margin = 79.94% ((Revenue TTM 155.8m - Cost of Revenue TTM 31.3m) / Revenue TTM)
Tobins Q-Ratio = -0.47 (set to none) (Enterprise Value 470.9m / Book Value Of Equity -997.7m)
Interest Expense / Debt = 3.71% (Interest Expense 11.0m / Debt 296.2m)
Taxrate = 21.0% (US default)
NOPAT = -145.8m (EBIT -145.8m, no tax applied on loss)
Current Ratio = 3.13 (Total Current Assets 373.8m / Total Current Liabilities 119.5m)
Debt / Equity = 1.39 (Debt 296.2m / last Quarter total Stockholder Equity 213.7m)
Debt / EBITDA = -2.28 (Net Debt 192.1m / EBITDA -129.9m)
Debt / FCF = -1.69 (Debt 296.2m / FCF TTM -175.6m)
Total Stockholder Equity = 262.2m (last 4 quarters mean)
RoA = -30.22% (Net Income -175.6m, Total Assets 581.0m )
RoE = -66.95% (Net Income TTM -175.6m / Total Stockholder Equity 262.2m)
RoCE = -28.58% (Ebit -145.8m / (Equity 262.2m + L.T.Debt 247.8m))
RoIC = -55.59% (NOPAT -145.8m / Invested Capital 262.2m)
WACC = 6.96% (E(498.1m)/V(794.2m) * Re(9.35%)) + (D(296.2m)/V(794.2m) * Rd(3.71%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.60%
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -175.6m)
EPS Correlation: 59.18 | EPS CAGR: 60.62% | SUE: -2.17 | # QB: 0
Revenue Correlation: 21.78 | Revenue CAGR: -7.56% | SUE: N/A | # QB: None
Additional Sources for RGNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle